<DOC>
	<DOCNO>NCT00145600</DOCNO>
	<brief_summary>With success current chemotherapy Hodgkin 's disease , goal protocol maintain currently successful cure rate reduce treatment related side effect long term toxicity . The main purpose study estimate event free survival patient treat risk-adapted therapy compare historical control .</brief_summary>
	<brief_title>Therapy Pediatric Hodgkin Lymphoma</brief_title>
	<detailed_description>This study evaluate follow objective : Primary Objectives : 1 . To evaluate efficacy 4 cycle VAMP chemotherapy alone patient favorable risk Hodgkin 's disease achieve complete response 2 cycle VAMP chemotherapy . 2 . To evaluate efficacy 4 cycle VAMP chemotherapy plus low dose RT patient favorable risk Hodgkin 's disease achieve partial response 2 cycle VAMP chemotherapy . 3 . To evaluate efficacy 2 alternate cycle VAMP/COP chemotherapy ( total 4 cycle chemotherapy ) plus low-dose , involved-field RT child intermediate risk Hodgkin 's disease . 4 . To evaluate efficacy 12 week Stanford V chemotherapy plus low-dose , involved-field RT child unfavorable risk Hodgkin 's disease . Secondary Objectives : 1 . To evaluate patient quality life treatment patient parent perspective . 2 . To compare patient parental rating treatment-related symptom patient physical , psychological , social cognitive function first treatment ( T1 - baseline ) ; Cycle 2 8 week Stanford V ( T2 - Evaluate Response ) ; cycle 4 12 week Stanford V first day radiation ( applicable ) ( T3 ) ; conclusion radiation within day follow end radiation ( applicable ) ( T4 ) ; 3 6 month completion therapy follow-up evaluation ( T5 ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>General Eligibility Criteria : 1 . Eligible patient must histologically confirm previously untreated Hodgkin 's disease ( Patients receive limited emergent RT steroid therapy cardiopulmonary decompensation spinal cord compression eligible protocol enrollment ) . 2 . Patients must 21 year age younger 3 . Ann Arbor stag IIBIV 4 . No prior treatment . 5 . No pregnant lactate woman . 6 . Signed informed consent 7 . If reevaluation patient 's disease show favorable risk feature intermediate risk feature , patient remove HOD99 study consent respective HOD08 HOD05 study . Eligibility treatment favorable risk feature : 1 . Ann Arbor stage IA IIA : 1 . Nonbulky mediastinal disease ( &lt; 33 % mediastinal thoracic ratio chest xray ) 2 . &lt; 3 nodal region involve side diaphragm 3 . No `` E '' lesion Eligibility treatment intermediate risk feature : 1 . Stage must classify one following : 1 . Ann Arbor stage IB IIIA 2 . Ann Arbor stage IA IIA ANY follow feature : ( 1 ) `` E '' lesion ( ) , ( 2 ) 3 nodal site involve , ( 3 ) Bulky mediastinal adenopathy ( mediastinal mass thoracic cavity ratio 33 % great chest radiograph ) Eligibility unfavorable risk feature : 1 . Stage must classify one following : a. Ann Arbor stage IIB , IIIB , IV</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Hodgkin Disease</keyword>
</DOC>